ClinicalTrials.gg
CompletedNCT06405152AMETHYSTUpdated Oct 5, 2026

Assessment of Macrophage Activation syndromE in STill's Disease

An observational study in Macrophage Activation Syndrome, Still's Disease, Adult-Onset and Stills Disease, Juvenile-Onset, sponsored by Swedish Orphan Biovitrum. Completed at 11 sites in 7 countries. Open to participants aged 6 Months to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Swedish Orphan Biovitrum · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
75
Ages
6 Months to 80 Years
Sex
All
01

Study summary

Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics

Read the detailed description

This is an observational, retrospective cohort study on the treatment utilization and outcomes of Macrophage Activation Syndrome (MAS) refractory to glucocorticoids (GC) in patients with Still's disease. The study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments.

02

Conditions studied

  • Macrophage Activation Syndrome
  • Still's Disease, Adult-Onset
  • Stills Disease, Juvenile-Onset
03

In context

Macrophage Activation Syndrome

20 studies on the registry are indexed under Macrophage Activation Syndrome; 4 are open to participants now.

Browse Macrophage Activation Syndrome studies →

Lead sponsor

Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will include patients with Still's disease who were diagnosed with MAS that was refractory to GC treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >6 months and ≤80 years at the beginning of the index MAS episode.
  • Diagnosis of Still's disease (sJIA (systemic Juvenile Idiopathic Arthritis) or AOSD (Adult Onset Stills Disease) diagnosis).
  • Diagnosis of MAS according to treating physician in the medical record.
  • Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be to GC due to clinical worsening of patient's condition .
  • The onset of the index MAS episode occurred between 01 January 2012 and 30 September 2022.

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of primary Hemophagocytic Lymphohistiocytosis (HLH) prior to the beginning of the index MAS episode.
  • Confirmed prior to the beginning of the index MAS episode.
  • Patient treated with any product as a part of clinical trial during the index MAS episode.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
75 participants (actual)
Patient registry
No

Interventions

  • OtherChart review

    Retrospective Chart Review

06

What researchers measure

Primary outcomes

  1. Overall survival

    The proportion of patients alive after 1-year of follow-up

    Time frame: 1 year

  2. Time to laboratory value normalization

    Time to normalization for the key laboratory values

    Time frame: From Index date up to 26 weeks

  3. Time to Macrophage Activation Syndrome (MAS) laboratory remission

    Time to normalization for all key laboratory values

    Time frame: From Index date up to 26 weeks

  4. Time to partial MAS laboratory remission

    Time to normalization for at least 3 key laboratory values

    Time frame: From Index date up to 26 weeks

  5. Time to tapering of Glucocorticoids (GCs)

    From index date to the last of 7 consecutive days receiving ≤1 mg/kg/day of prednisone (PDN).

    Time frame: from index date to the last of 7 consecutive days

  6. Number of recurrent MAS episodes

    Occurring any time after the end of the data collection period for the index MAS episode

    Time frame: through study completion

  7. Administration of organ support care

    Proportion of patients receiving hemodialysis, assisted ventilation, cardiac support, or inotropic drugs

    Time frame: from the index date until either the end of hospitalization or 26 weeks, whichever occurs later

  8. Characteristics of MAS treatment

    description of treatment patterns of MAS-related treatments for both index and recurrent MAS episodes.

    Time frame: for MAS episodes occurring during the data collection period

  9. Clinical signs

    No of MAS symptoms (Fever, Skin rash, Hemorrhagic manifestations, Evidence of CNS involvement) present

    Time frame: At index date and 8 weeks after index date or at the earliest time this data becomes available between 8 and 12 weeks

Secondary outcomes

  1. Time to hospital discharge

    Defined as time from the index date to discharge from the hospital

    Time frame: Up to 26 weeks

  2. Time to intensive care unit (ICU) discharge

    For patients who are admitted to the ICU during the index MAS episode, this is defined as time from index date or ICU admission (whichever comes later) to ICU discharge

    Time frame: Up to 26 weeks

  3. Duration of Clinical Response

    defined as the time (in days) from the date of first documented MAS laboratory remission until the date of first documented occurrence of a new MAS episode as per investigator's assessment.

    Time frame: Until week 26

07

Study locations

11 sites
  • Swedish Orphan Biovitrum Research Site
    Los Angeles, California 90095, United States
  • Swedish Orphan Biovitrum Research Site
    Atlanta, Georgia 30329, United States
  • Swedish Orphan Biovitrum Research Site
    Cincinnati, Ohio 45229, United States
  • Swedish Orphan Biovitrum Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Swedish Orphan Biovitrum Research Site
    Calgary, Canada
  • Swedish Orphan Biovitrum Research Site
    Paris, France
  • Swedish Orphan Biovitrum Research Site
    Heidelberg, Germany
  • Swedish Orphan Biovitrum Research Site
    Milan, Italy
  • Swedish Orphan Biovitrum Research Site
    Rome, Italy
  • Swedish Orphan Biovitrum Research Site
    Utrecht, Netherlands
  • Swedish Orphan Biovitrum Research Site
    Barcelona, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Sep 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
May 8, 2024
StartActual
Sep 27, 2023
Primary completionActual
Sep 26, 2024
CompletionActual
Sep 26, 2024
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: site details and index terms
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 2 other changes: site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06405152
Responsible party
Sponsor
First posted
May 8, 2024
Start date
Sep 27, 2023
Primary completion
Sep 26, 2024
Completion
Sep 26, 2024
Last update
Oct 5, 2026

Study contacts

Uwe Ullman, MD
study director · Swedish Orphan Biovitrum AG Riehenring 182, 4058 Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion